[Amoxicillin/clavulanic acid (875/125 mg). New pharmacodynamic aspects].
Lode
H
H
Schwerpunkt Infektiologie und Immunologie, Krankenhaus Zehlendorf-Krankenhausbetrieb von Berlin, Bereich Heckeshorn.
D000284:Administration, Oral; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D001991:Bronchitis / Q000188:drug therapy; D004311:Double-Blind Method; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D006192:Haemophilus Infections / Q000188:drug therapy; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D001936:Moraxella catarrhalis / Q000187:drug effects; D015337:Multicenter Studies as Topic; D016870:Neisseriaceae Infections / Q000188:drug therapy; D011014:Pneumonia / Q000188:drug therapy; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D012141:Respiratory Tract Infections / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D013211:Staphylococcus aureus / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects
D000900:Anti-Bacterial Agents; D019980:Amoxicillin-Potassium Clavulanate Combination